Physician profile
Benjamin Mann
NPI 1952595373
$3,146.60
in general payments reported to CMS, 2019-2025
41 companies · $646 in 2025
The $646 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $879 · 2022: $960 · 2023: $640 · 2024: $21.35 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.19 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $327.74 | 2021-2023 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.88 | 2021-2023 | Jardiance, Synjardy, Spiriva |
| Bayer Healthcare Pharmaceuticals INC. | $201.08 | 2021-2023 | |
| Abbvie INC. | $175.74 | 2021-2023 | |
| Janssen Biotech, INC. | $166.74 | 2025 | Tremfya |
| Amarin Pharma, INC. | $129.81 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $122.25 | 2021-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Ucb, INC. | $114.90 | 2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $107.94 | 2021-2023 | |
| Esperion Therapeutics, INC. | $102.82 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $100.86 | 2025 | Dupixent |
| Novo Nordisk INC | $93.74 | 2021-2024 | Wegovy |
| Pfizer INC. | $87.20 | 2021-2022 | |
| Amgen INC. | $84.71 | 2021-2025 | Otezla, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $80.11 | 2021-2023 | Farxiga |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.